New drugs for treating small cell lung cancer.
Recently there has been a number of new active drugs which have been identified for treating patients with SCLC. These drugs include paclitaxel, docetaxel, CPT-11, topotecan and gemcitabine. The range of response rates are as follows for each of the drugs given: (1) to previously untreated patients: paclitaxel (34-41%), topotecan (39%) and gemcitabine (30%), and (2) to previously treated patients: docetaxel (28%), CPT-11 (47%) and topotecan (35%). Further studies with these new drugs utilized in combination chemotherapeutic regimens are needed to define the role of these agents in the treatment of patients with SCLC.
Ettinger
D S
DS
Johns Hopkins Oncology Center, Baltimore, MD, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077143:Docetaxel; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000627:therapeutic use; D043823:Taxoids; D019772:Topotecan; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000077146:Irinotecan; D019772:Topotecan; D017239:Paclitaxel; D002166:Camptothecin; D000093542:Gemcitabine